Dr. Rosenheck and colleagues reply [2]

American Journal of Psychiatry

Volumn 164, Issue 4, 2007, Pages 678-680

  Rosenheck, Robert ^a   Stroup, T Scott ^a   Swartz, M ^a   McEvoy, Joseph ^a   Davis, Sonia M ^a   Keefe, Richard S E ^a   Hsiao, John K ^a   Lieberman, J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG POTENCY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; FOLLOW UP; HEALTH CARE POLICY; HUMAN; LETTER; META ANALYSIS; NEUROLOGIC DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; SIDE EFFECT; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; WEIGHT GAIN;

EID: 34247510772     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.2007.164.4.678a     Document Type: Letter

References (10)

1. Polsky D, Doshi JA, Bauer MS, Glick HA: Clinical trial-based cost-effectiveness analyses of antipsychotic use. Am J Psychiatry 2006; 163:2047-2056
2. Correll CU, Leucht S, Kane JM: Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004; 161:414-425
3. Leucht S, Wahlbeck K, Hamann J, Kissling W: New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003; 361:1581-1589
4. Freedman R, Carpenter WT Jr, Davis JM, Goldman HH, Tamminga CA, Thomas M: The costs of drugs for schizophrenia (editorial). Am J Psychiatry 2006; 163:2029-2031
5. Lieberman JA, Stroup S, McEvoy J, Marvin Swartz, Rosenheck R, Perkins D, Keefe RSE, Davis S, Davis CE, Hsiao J, Severe J, Lebowitz B: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: primary efficacy and safety outcomes of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. N Engl Med 2005; 353:1209-1223
6. Tollefson GD, Beasley CM Jr, Tran PV, Street J, Krueger J, Tamura RN, Graffeo K, Thieme M: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154:457-465
7. Correll CU, Leucht S, Kane JM: Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004; 161:414-425
8. Polsky D, Doshi JA, Bauer MS, Glick HA: Clinical trial-based cost-effectiveness analyses of antipsychotic use. Am J Psychiatry 2006; 163:2047-2056
9. Bekelman JE, Li Y, Gross CP: Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 2003; 289:454-465
10. Lexchin J, Bero LA, Djulbegovic B, Clark O: Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003; 326:1167-1170